Allergy Therapeutics expands its microbiology diagnosis facilities in Spain to include COVID-19 tests

Allergy Therapeutics Ibérica, subsidiary of the British bio-pharmaceutical firm Allergy Therapeutics PLC and member of CataloniaBio & HealthTech, has expanded its facilities in Alcalá de Henares (Madrid) to conduct SARS-CoV-2 diagnosis tests through the RT-PCR test. Allergy Therapeutics Ibérica also has offices in Sant Joan Despí (Barcelona).

The new laboratory is called ATImmunolab and will be able to conduct up to 200,000 tests per year when it reaches maximum capacity. The project has received financing from the Centre for Technological Industrial Development (CDTI) and from the technological fund of the Spanish Ministry of Science and Innovation.

PCR is the cutting-edge technique that is recommended for detecting positive cases within the first stages of COVID-19 infection.

Gloria Garcia Cadena, General Manager of Allergy Therapeutics Ibérica, told us that "our culture of innovation has led us to do everything possible to do our part in this healthcare crisis. The new space set aside for COVID-19 will give us the chance to speed up diagnoses for SARS-CoV-2 and, in the long term, support related research projects.”

Furthermore, Manuel Llobet, CEO of Allergy Therapeutics, wished to draw attention to “the interdisciplinary experience in biotechnology, microbiology, biochemistry and immunology that our R&D teams have.”

Allergy Therapeutics has over 40 years of experience in researching and developing diagnostic tools and vaccines to be used in the field of allergies and infectious diseases, and they currently have a team of over 600 employees across Europe.